by Ishai Menache, Jeevan Pathuri, David Simchi-Levi and Tom Linton Companies face a variety of complex challenges in designing and optimizing their supply chains. Increasing their resilience ...

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

At issue is the role pharmacy benefit mangers play in taking large discounts on drugs that advocates say are not passed along ...

A key provision in the new legislation could affect compensation for brokers or consultants who help employers hire pharmacy ...